Balchem Corp. 10-K Summary: Fiscal Year Ended December 31, 2000
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2000, for Balchem Corporation, a Maryland-based company incorporated in 1967. The company develops, manufactures, and markets specialty performance ingredients for the food, feed, and medical sterilization industries. Operations are divided into two segments: Encapsulated Products (micro-encapsulation for food and animal health) and Specialty Products (repackaging and marketing of specialty gases like ethylene oxide). The company operates facilities in Slate Hill, New York, and Green Pond, South Carolina.
Key Financial Metrics
| Metric (in thousands, except per share) | 2000 | 1999 |
|---|---|---|
| Net Sales | $33,198 | $29,682 |
| Gross Profit | $14,041 | $12,124 |
| Gross Margin | 42.3% | 40.8% |
| Net Earnings | $3,729 | $3,094 |
| Diluted EPS | $0.78 | $0.63 |
| Operating Cash Flow | $5,953 | $4,682 |
| Long-Term Debt | $0 | $1,250 |
| Cash and Equivalents | $3,068 | $1,699 |
| Total Assets | $23,222 | $22,030 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12% to $33.2 million. The Encapsulated Products segment drove this growth with a 33% increase in sales ($13.1 million), attributed to new product launches (Reashure(TM)) and expanded sales representation. The Specialty Products segment saw a modest 1% increase ($20.1 million).
- Profitability: Net earnings rose 20% to $3.7 million. Gross margins improved to 42.3% due to production efficiencies and a favorable product mix. The Encapsulated Products segment turned a $600,000 operating loss in 1999 into a $333,000 operating profit in 2000.
- Debt Elimination: The company paid off its remaining long-term debt of $1.25 million during 2000, resulting in net interest income of $58,000 compared to interest expense of $111,000 in 1999.
- Share Repurchases: The company repurchased 214,916 shares of treasury stock in 2000 at a cost of $2.2 million, part of a program authorized in 1999.
Outlook, Risks, and Contingencies
- Regulatory Risk (EPA): The company's ability to sell ethylene oxide depends on EPA re-registration. While testing is complete, the EPA has not set a completion date due to a backlog. Management believes re-registration will be successful as the product has no known equally effective substitute.
- Customer Concentration: One customer (IBA) accounted for approximately 13% of net sales in 2000. The loss of this customer could have a material adverse effect.
- Environmental Compliance: The company is subject to California Proposition 65 regarding ethylene oxide as a carcinogen. It is also involved in ongoing monitoring of a remediation site in Slate Hill, NY, with historical costs under $10,000 annually.
- Capital Expenditures: Capital expenditures were $881,000 in 2000 and are projected to be approximately $1.8 million for 2001.
- Liquidity: Management believes current cash balances and operating cash flow are sufficient to fund operations for the next year. The company maintains a $2.0 million line of credit with no outstanding borrowings.
Investor Verification Checklist
- Verify the status of the EPA re-registration for ethylene oxide and potential timelines for approval.
- Assess the stability of the relationship with the key customer (IBA) representing 13% of sales.
- Review the sustainability of the 33% sales growth in the Encapsulated Products segment and the performance of the new Reashure(TM) product.
- Confirm the company's ability to maintain gross margins above 42% given potential raw material price fluctuations.
- Monitor the progress of the Slate Hill, NY environmental site monitoring and any potential for increased remediation costs.